Inhibition of Xanthine Oxidoreductase Enhances the Potential of Tyrosine Kinase Inhibitors against Chronic Myeloid Leukemia

• Main Authors: Marta Romo-González (Author), Sara Moreno-Paz (Author), Violeta García-Hernández (Author), Fermín Sánchez-Guijo (Author), Ángel Hernández-Hernández (Author)
• Formato: Livro
• Publicado em: MDPI AG, 2020-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Chronic myeloid leukemia (CML) is characterized by the expression of the oncogenic kinase BCR-ABL. Although tyrosine kinase inhibitors (TKIs) against BCR-ABL represent the standard therapeutic option for CML, resistances to TKIs can be a serious problem. Thus, the search for novel therapeutic approa...